XELOX doublet regimen versus EOX triplet regimen as first‐line treatment for advanced gastric cancer: An open‐labeled, multicenter, randomized, prospective phase III trial (EXELOX)

BACKGROUND: There is no consensus on whether triplet regimen is better than doublet regimen in the first‐line treatment of advanced gastric cancer (AGC). We aimed to compare the efficacy and safety of oxaliplatin plus capecitabine (XELOX) and epirubicin, oxaliplatin, plus capecitabine (EOX) regimens...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Xiao‐Dong, Huang, Ming‐Zhu, Wang, Yu‐Sheng, Feng, Wan‐Jing, Chen, Zhi‐Yu, He, Yi‐Fu, Zhang, Xiao‐Wei, Liu, Xin, Wang, Chen‐Chen, Zhang, Wen, Ying, Jie‐Er, Wu, Jun, Yang, Lei, Qin, Yan‐Ru, Luo, Jian‐Feng, Zhao, Xiao‐Ying, Li, Wen‐Hua, Zhang, Zhe, Qiu, Li‐Xin, Geng, Qi‐Rong, Zou, Jian‐Ling, Zhang, Jie‐Yun, Zheng, Hong, Song, Xue‐Feng, Wu, Shu‐Sheng, Zhang, Cheng‐Yan, Gong, Zhe, Liu, Qin‐Qin, Wang, Xiao‐Feng, Xu, Qi, Wang, Qi, Ji, Jian‐Mei, Zhao, Jian, Guo, Wei‐Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017757/
https://www.ncbi.nlm.nih.gov/pubmed/35212487
http://dx.doi.org/10.1002/cac2.12278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017757/
https://www.ncbi.nlm.nih.gov/pubmed/35212487
http://dx.doi.org/10.1002/cac2.12278

Ejemplares similares